Scoop: Bing Yao’s Ar­riVent lin­ing up $145M raise, af­ter $150M de­but in 2021

Bing Yao took his pre­vi­ous biotech through three key mile­stones: IPO, drug ap­proval and an M&A ex­it. Now, he’s lin­ing up an­oth­er round of fi­nanc­ing for his bet on bring­ing Chi­nese R&D to the States.

Ar­riVent Bio­phar­ma de­buted with a $150 mil­lion round in June 2021. New pa­per­work filed with the SEC last week out­lines a sec­ond round of fi­nanc­ing is in the works for up to $145 mil­lion. The fil­ing doc­u­ments 17 in­vestors so far lin­ing up $110 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER